Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the countries that are slightly
better, finland, norway, are doing things, that could not be done
here.
even the states that do it right, get wiped out by interstate
travel. my understanding is that finland, norway, stop people at the border
and quarantine for a period of time.
that would have very little chance of happening here.
until there is a vaccine, or it runs it course, it will take
who it wants.
95% of the people wearing a mask, would slow the death count,
and give science time to catch up. best.
sweden not doing so well,
at least, not as well as the fins, and norway.
https://www.msn.com/en-us/news/world/as-second-covid-wave-spreads-swedens-anti-lockdown-top-doc-sidelined/ar-BB1brY6D?ocid=msedgdhp
suppose about 18 to 38 years of age,
is when we are most social. (not counting school)
always have said that when i was young, it was a penalty,
if i couldn't go out, now its a penalty if i have to go out.
" Start with the first responders, healthcare workers, fire departments, police. Then put grocery workers at the top of the list, as they deal with almost everyone everyday.
But vaccinating super spreaders nips many problems in the bud."
tough decisions. best.
suppose it depends on which group takes the vaccine.
when we are are young, we want to run, be with others.
be social, mingle.
as we age, stay at home becomes the thing, or at least
more acceptable.
a lot of this is still anybody's guess, IMO.
fauci has been at this a long time,
should have a good idea what the odds are, still,
someone else may come up with different numbers.
best.
(in other words, give shots to those who run)
most likely the frontline workers
will get the vaccine first, second LTC, and their workers.
should take some of the pressure off these groups.
have doubts that they will be able to get more than 70% ,if that,
of the general population to take them.
good luck with that.
The infectious disease expert said that it's important "to make sure the overwhelming majority of the people in the country get vaccinated," and that even a 50 percent vaccination rate would leave the U.S. with a "considerable public health challenge" on our hands. "At least 80 to 85 percent" of people would need to be vaccinated to meaningfully reduce infection rates, Fauci explained.
https://www.msn.com/en-us/health/medical/dr-fauci-says-this-many-people-need-to-get-vaccinated-to-stop-covid/ss-BB1b6myp?ocid=msedgdhp
rlftf use.
hospitals must be able to ask for these drugs.
https://nptelegraph.com/news/local/watch-now-great-plains-health-only-hospital-in-nebraska-helping-test-covid-19-drug/article_db0bb030-25f8-11eb-bfb3-73b7242b5df1.html#tracking-source=home-top-story
dr. osterholm PBS interview.
over the noon hour, good interview, hope some of you caught
it.
will need All the vacines.
still a problem to get people to take them.
perhaps a link will show up in the coming days.
(dr. osterholm member of biden Advisory Board.)
mayo-hgen-rec-for
inpatients.
https://kcmsprodkmstaticncstg.blob.core.windows.net/ame/MayoClinic_RST_Inpatient-treatment-algorithm.pdf
should add that vxrt is
a large gamble, they are small in a large bio world.
any bad news will put the price back at a dollar or two.
hold a small portion of it, know the risk.
biggest concern for me is that a small bio may not get the same
treatment from the fda that a large company will.
may be other factors, politics, behind the curtain that
can't be seen.
ot i have a autoimmune illness,
causes more acid reflux than normal.
chest pain comes with it.
for me it comes down to,
does the pill work or does it not.
should have some idea before the end of the year.
best.
side affects,
still better than the virus. most likely to come with all
vaccines.
https://nypost.com/2020/11/11/pfizers-vaccine-volunteers-say-it-felt-like-severe-hangover/
the way it is.
https://www.weforum.org/agenda/2018/07/the-biggest-hurdle-to-universal-vaccination-might-just-be-a-fridge
vasart, pill, still has a shot.
the way it is.
https://www.weforum.org/agenda/2018/07/the-biggest-hurdle-to-universal-vaccination-might-just-be-a-fridge
which to me means vasart and others, still have a shot.
(getting product to market, if it works, and is say, 70-80% effective)
c. v.
Fauci said new research out this week makes an even stronger case for masks. Whereas experts have pitched masks as a mitigation effort that protects others, Fauci said it now appears that mask-wearers also protect themselves by using face coverings.
"Recent studies have shown it's both ways now," he said. "It's a two-way street."
https://www.msn.com/en-us/news/us/fauci-optimistic-about-covid-19-vaccine-says-high-risk-could-get-it-in-december/ar-BB1aSFqq?ocid=msedgdhp
very good imo.
you have to watch a promotion, but worth it.
https://www.msn.com/en-us/health/medical/dr-william-haseltine-says-virus-is-very-serious-despite-successful-pfizer-vaccine-trial/vi-BB1aQtWf?ocid=msedgdhp
rlftf for cancer, inhaled,
hope it translates to english.
https://www.gesundheitsindustrie-bw.de/fachbeitrag/aktuell/inhalation-von-darmhormon-vip-hilft-gegen-immuntherapiebedingte-lungenentzuendung
U.K. priority list.
https://twitter.com/Gabriel_Pogrund/status/1322646595658272768/photo/1
vasart made priority top in p-1
lot of heavy weights in p2 and p3
MicroneedleVirtualConference
https://www.pharmaedresources.com/conferences/MicroneedleVirtualConference2020.cfm
possible stimulus package
could cause a rise in some of the vaccine companies, with
hope that there would be ows funding.
also, sounds like c.v. transmitting mostly airborne.
https://www.msn.com/en-us/health/medical/stop-wiping-down-groceries-and-focus-on-bigger-risks-say-experts-on-coronavirus-transmission/ar-BB1aiqpp?ocid=msedgdhp
spread out to far,
not the best control over the whole trail, i take it to be.
did add some zsan, any thoughts on their future.
covid 19 guidelines.
seems who and nih are opposite on some of this. (remdesivir)
https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/
yes, seen the bloomberg story.
time will tell, everything has risk.
like the mayo connection. lot of players in the field.
best.
Cantor Fitzgerald initiates coverage with a $25 target
Investment Summary. We are initiating coverage of HGEN shares with an OW rating
and 12-month PT of $25. We arrive at our PT by using a DCF analysis. HGEN's lead
product candidate, lenzilumab, is a mAb designed to neutralize GM-CSF. We expect
upwards earnings revisions from the successful commercialization of three indications
for lenzilumab to drive HGEN shares higher. These include the use of lenzilumab: 1)
As a therapy for hospitalized patients with COVID-19 pneumonia, and Phase 3 data are
expected in 4Q20; 2) As a sequenced therapy ahead of CAR-T administration, Phase 1b
ZUMA-19 results are expected 1Q21; and 3) As an early treatment/prophylaxis for SRaGvHD, HGEN will complete planning for a registration study in the UK 4Q20 and begin
enrollment in 1H21.
¦ Expecting positive Phase 3 data for COVID-19 opportunity. Lenzilumab could be the
first antibody approved for cytokine storm associated with COVD-19, and HGEN could
make up to $1B in sales in 2021, if the drug is given EUA. We are expecting HGEN
to report positive, Phase 3 data 4Q20. This is supported by the published data from
the Mayo Clinic. The Mayo data was from a 39-patient case-controlled study. Twelve
patients were treated with lenzilumab and were compared to 27 similar patients
on SoC. The data showed that: 1) The time to clinical improvement was shorter
for lenzilumab: 5 days vs. 11 and 2) Ventilator-free survival was much better for
lenzilumab vs. SoC. HGEN is also participating in the NIH-sponsored ACTIV-5/Big Effect
Trial. These data will likely read out in 1H21. Importantly, lenzilumab is a 1-day course
of therapy that compares favorably to Remdesivir, which runs ~5 days. Finally, a paper
published on 10/14 (link here) adds more weight to GM-CSF as a target for COVID-19.
See our COVID-19 mAb tracker here for more details on the competitive landscape.
¦ Lenzilumab could change treatment paradigm & expand market for CAR-T. There is
evidence linking early elevation of GM-CSF to serious and potentially life-threatening
side effects in CAR-T therapy (neurotoxicity and CRS). Pre-clinical lenzilumab data
have supported its potential to prevent CRS and significantly reduce neurotoxicity,
and have shown an increase in CAR-T cell expansion when lenzilumab is administered
prophylactically in combination with CAR-T. This could expand the use of CAR-Ts
and the market opportunity for lenzilumab. There are currently no FDA-approved
therapies for the prevention of the serious side-effects associated with CAR-T. Positive
data could support putting all/most CAR-T patients on sequenced therapy with
lenzilumab. HGEN is collaborating with Kite/GILD (OW, covered by A. Young) on the
ZUMA-19 study. HGEN's goal is to complete the Phase 1b part this year and move
into the Phase 2 study next year. HGEN is also looking to study sequencing lenzilumab
ahead of other CAR-T therapies.
¦ Lenzilumab could change treatment paradigm for SR-aGvHD. Recent studies have
found GM-CSF to be an important pathogenic cytokine in aGvHD. Donor T cells that
secrete GM-CSF promote GvHD by recruiting donor dendritic cells, which amplifies the
activation of alloreactive T cells and increases the severity of GvHD. Therefore, GMCSF neutralization has the potential to prevent or treat GvHD in patients undergoing
allogeneic HSCT. HGEN has been approached by a group called the Impact Partnership,
which is a partnership of 23 transplant centers in the UK that treat the majority of
UK patients and also run clinical trials as part of the network. ~50% of all patients
with aGvHD will be intermediate/high risk of SR-aGvHD and would be eligible for
lenzilumab based on the IMPACT protocol. If successful in early treatment of SRaGvHD, HGEN would look to position lenzilumab as prophylaxis of aGvHD with further
clinical development.
not good news for
us older males, interesting.
https://www.msn.com/en-us/news/world/why-the-coronavirus-is-killing-more-men-than-women/ar-BB1a7TaS?ocid=msedgdhp
Lenzilumab could aid in the
expansion of CAR-T by allowing for a higher CAR-T dose, potentially improving efficacy
and reducing patient hospitalization.
https://9e234b13-0cc4-4c74-b924-d7874342289e.filesusr.com/ugd/6ca631_da982beaeaea4f19a576cc8f37bf0215.pdf
wonder if trials will proceed as quite a few
are in combination. perhaps WHO will not be taken seriously.
Breaking News: The Covid-19 treatment remdesivir has no substantial effect on a patient’s chances of survival, a clinical trial by the World Health Organization has found https://t.co/x6BShx62kW pic.twitter.com/muLo3hSeYk
— Financial Times (@FinancialTimes) October 15, 2020